UPDATE : Friday, August 23, 2019
상단여백
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
The accounting fraud allegation involving Samsung BioLogics has been one of...
by Lee Han-soo  |  2019-07-19 18:16
라인
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
Samsung Bioepis said that the European Medicines Agency (EMA) has started e...
by Lee Han-soo  |  2019-07-19 17:01
라인
Celltrion targets Chinese biosimilar market through joint venture
Celltrion said it has established Vcell Healthcare Ltd., a joint venture wi...
by Lee Han-soo  |  2019-07-19 14:53
라인
Biopharmaceutical stocks face grim outlook in 2H
Biopharmaceutical stocks remain sluggish in the second half. Stock prices h...
by Jeong Sae-im  |  2019-07-17 14:11
라인
Celltrion starts P1 trial of Xolair biosimilar
Celltrion said Monday that it initiated the phase 1 clinical trial of CT-P3...
by Lee Han-soo  |  2019-07-15 17:45
라인
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
Colon cancer specialists questioned SillaJen’s allegation that the combinat...
by Jeong Sae-im, Kim Yun-mi  |  2019-07-12 15:13
라인
Court suspends decision on ministry’s order to revoke Invossa license
The Seoul Administrative Court on Thursday said it has temporarily suspende...
by Jeong Sae-im  |  2019-07-12 13:11
라인
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
The prosecution raided two securities firms that managed the initial public...
by Jeong Sae-im  |  2019-07-11 16:39
라인
NKMax America seeks NASDAQ listing in 2020
“With NASDAQ listing in October next year, we will show the excellent effic...
by Jeong Sae-im  |  2019-07-11 12:41
라인
Psomagen seeks KOSDAQ listing using technology exception policy
Psomagen, a U.S. subsidiary of Macrogen, said it would use Korea’s “technol...
by Jeong Sae-im  |  2019-07-10 15:20
라인
Kolon files administrative suit against Invossa license revocation
Kolon Life Science said it has filed an administrative lawsuit against the ...
by Jeong Sae-im  |  2019-07-09 11:47
라인
SillaJen shareholders panic over exec’s selling of 160,000 stocks
An executive at SillaJen suddenly sold 160,000 shares for “personal reasons...
by Jeong Sae-im  |  2019-07-09 11:45
라인
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless
The stock market operator said it would review whether to keep Kolon Tissue...
by Jeong Sae-im  |  2019-07-08 12:06
라인
Victims question Kolon CEO’s sincerity in apology
Oh Kims Law & Co., leading a lawsuit against Kolon Life Science on behalf o...
by Jeong Sae-im  |  2019-07-05 15:14
라인
Samsung, Genentech settle patent dispute on Herceptin biosimilar
Samsung Bioepis has settled a patent infringement case with Genentech, a su...
by Lee Han-soo  |  2019-07-05 11:47
라인
Kolon confident to resume US trial on Invossa
The government has decided to nullify Invossa-K’s license effective next Tu...
by Lee Hye-seon  |  2019-07-04 14:05
라인
China OKs Alteogen’s Herceptin biosimilar for clinical trials
Alteogen said that Qilu Pharmaceutical, its Chinese partner, has received i...
by Lee Han-soo  |  2019-07-04 14:04
라인
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’
Kolon Life Science CEO said he would seek an administrative suit against th...
by Lee Hye-seon  |  2019-07-03 11:52
라인
BNO BIO to invest $1 million in Israeli biotech venture
BNO BIO, a joint venture between Bukwang Pharm and chemical and energy comp...
by Jeong Sae-im  |  2019-06-28 16:10
라인
Shareholders in shock over HLB’s phase-3 trial setback
Investors in HLB have expressed shock after the KOSDAQ-listed firm announce...
by Jeong Sae-im  |  2019-06-28 10:47
여백
여백
여백
Back to Top